Fibrocell Science (FCSC) Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 to Treat RDEB
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Fibrocell Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
September 19, 2016 8:01 AM EDTEXTON, Pa., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC) today announced that two additional adult subjects were enrolled in the Phase I/II clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), satisfying enrollment in one of two cohorts in the Phase I portion of the trial.
We are excited about the steady progress of the trial, as four of the six adult RDEB patients required for the Phase I portion of the study have been enrolled since late July, said David Pernock,... More